On February 2, the Beijing News reporter at the State Drug Administration Drug Review Center (CDE) website was informed that the new coronary pneumonia potential effective drug Redsiewe clinical trial application has been accepted. The drug is for Gilead, the company’s research drug, February 1, Beijing time, Gilead Sciences Global Chief Medical Officer Dr. Merdad Parsey issued a statement on behalf of the company, the company is working closely with the global health agencies to provide the research drug Remdesivir (Redsivir) for experimental treatment, to support the response to outbreaks of new coronavirus (2019-nCoV) infections.
In the early hours of February 1, the New England Journal of Medicine (NEJM), an authoritative medical journal, published several papers online on the 2019-nCoV case. One of them describes the course of treatment for the first confirmed case in the United States and its clinical manifestations of receiving Gilead Science’s experimental treatment of the drug Remdesivir (Redsivir) as a sympathetic drug. After treatment, the patient’s condition quickly eased.
Gilead also said it is working with China’s health authorities on a randomized, controlled trial to determine whether using Remdesivir to treat people infected with 2019-nCoV is safe and effective. Gilead is also pushing for appropriate laboratory testing of Remdesivir (Redsivir) using samples of the 2019-nCoV virus. According to the Global Clinical Trial database, Remdesivir’s clinical trial for the treatment of the new coronavirus will be launched on February 3 rdin-friendly hospital in Beijing.
Currently, Gilead is with the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services (DHHS), the China Centers for Disease Control and Prevention, The National Drug Administration (NMPA), the World Health Organization (WHO), Organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and researchers and clinicians are working together to contribute their resources in the field of antivirals to help patients and communities fight 2019-nCoV.
So far, Remdesivir has not been approved for listing in any country, and its safety and effectiveness have not been proven. Remdesivir is working on drugs and has no data for 2019-nCoV. In the absence of any approved treatment options, the treatment doctor weighed the risks and benefits before making a request for medication, and with the support of local regulators, Gilead provided the experimental drug Remdesivir for emergency treatment for a small number of people infected with 2019-nCoV.
Gilead said that while there is no antiviral data showing Remdesivir’s activity for 2019-nCoV, its valid data for other coronaviruses offers hope in both in vitro and animal models. Remdesivir confirmed that viral pathogens in atypical pneumonia (SARS) and Middle East Respiratory Syndrome (MERS) are active, they are also coronaviruses, and are structurally similar to 2019-nCoV. Clinical data on Remdesivir (Redsivir) emergency use to treat ebola virus infection sisivir are also limited.